Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SX 682

Next Previous
Drug Profile

SX 682

Alternative Names: SX-682

Latest Information Update: 07 Jul 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Syntrix Biosystems
  • Developer Boehringer Ingelheim; Bristol-Myers Squibb; National Cancer Institute (USA); Syntrix Biosystems; University of Rochester; University of Texas M. D. Anderson Cancer Center
  • Class Amides; Antineoplastics; Benzene derivatives; Boronic acids; Ethers; Fluorinated hydrocarbons; Fluorobenzenes; Pyrimidines; Small molecules
  • Mechanism of Action Interleukin 8A receptor antagonists; Interleukin 8B receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-small cell lung cancer; Prostate cancer
  • Phase I/II Colorectal cancer; Malignant melanoma; Myelodysplastic syndromes
  • No development reported Pancreatic cancer

Most Recent Events

  • 07 Jul 2026 National Cancer Institute plans a phase I/II trial for Head and Neck cancer, Salivary gland cancer and Prostate cancer (Late stage disease, Metastatic disease, Second line therapy or greater, Combination therapy) in USA (PO) in July 2026 (NCT07667400)
  • 05 Jan 2026 University of Washington plans a phase II trial for Non-small cell lung cancer (Late-stage disease, Metastatic disease, Recurrent, Second-line therapy or greater, Inoperable/Unresectable, Combination therapy) in USA (PO) (NCT07322341) in March 2026
  • 28 Apr 2025 Phase-I/II clinical trials in Prostate cancer (Metastatic disease, Hormone refractory, Combination therapy, Second-line therapy or greater) in Switzerland (PO) (NCT07002320)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top